GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Tau Medical Ltd (NAS:DRTS) » Definitions » Total Liabilities

DRTS (Alpha Tau Medical) Total Liabilities : $23.54 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Alpha Tau Medical Total Liabilities?

Alpha Tau Medical's Total Liabilities for the quarter that ended in Dec. 2024 was $23.54 Mil.

Alpha Tau Medical's quarterly Total Liabilities declined from Jun. 2024 ($22.03 Mil) to Sep. 2024 ($21.33 Mil) but then increased from Sep. 2024 ($21.33 Mil) to Dec. 2024 ($23.54 Mil).

Alpha Tau Medical's annual Total Liabilities increased from Dec. 2022 ($14.49 Mil) to Dec. 2023 ($22.91 Mil) and increased from Dec. 2023 ($22.91 Mil) to Dec. 2024 ($23.54 Mil).


Alpha Tau Medical Total Liabilities Historical Data

The historical data trend for Alpha Tau Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Tau Medical Total Liabilities Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 61.42 76.99 14.49 22.91 23.54

Alpha Tau Medical Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.91 23.38 22.03 21.33 23.54

Alpha Tau Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alpha Tau Medical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.675+(11.525+3.338
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.54

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=86.204-62.666
=23.54

Alpha Tau Medical's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.675+(11.525+3.338
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.54

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=86.204-62.666
=23.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Tau Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alpha Tau Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Tau Medical Business Description

Traded in Other Exchanges
N/A
Address
Kiryat Hamada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.